IL17A and colitis: The PI3K-AKT-mTOR-NF-κB axis was functionally validated in IL-10−/− NF-κB-EGFP mice showing enhanced colitis with bacterial dissemination and elevated CXCL2/IL-17α/IL-1β.258 Rapamycin (mTOR inhibitor) reduced bacterial persistence and inflammation while enhancing splenic clearance.